Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
Investigators believe that circulating adipokines may be associated with the development of preeclampsia in women with type 1 diabetes in the first trimester.
Investigators assess maternal hyperglycemia exposure to fetus with neonatal health outcomes.
Study assessed the effects of sotagliflozin vs placebo with respect to glycemic control and the occurrence of severe hypoglycemia and diabetic ketoacidosis among adults with type 1 diabetes.